Xenon Pharmaceuticals
XENE
70 hedge funds and large institutions have $314M invested in Xenon Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 13 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
38% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 13
28% more capital invested
Capital invested by funds: $245M → $314M (+$68.7M)
22% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 18
6.96% more ownership
Funds ownership: 72.3% → 79.26% (+7%)
6% more funds holding
Funds holding: 66 → 70 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$28.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$22.6M |
| 3 |
O
OrbiMed
New York
|
+$14.6M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$10.3M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
+$8.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$4.12M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.86M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.11M |
| 4 |
EP
Eversept Partners
New York
|
-$2.05M |
| 5 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$1.86M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Goldman Sachs
New York
| – | -$170K | -12,937 | Closed |
|
|
OAM
77
Oxford Asset Management
Oxford,
United Kingdom
| – | -$165K | -12,553 | Closed |
|
78
Invesco
Atlanta,
Georgia
| – | -$163K | -12,410 | Closed |
|
79
Bank of America
Charlotte,
North Carolina
| – | -$34K | -2,618 | Closed |
|
80
Citigroup
New York
| – | -$18K | -1,352 | Closed |
|
|
CG
81
Cutler Group
San Francisco,
California
| – | -$13.8K | -969 | Closed |
|
82
Wells Fargo
San Francisco,
California
| – | -$4K | -300 | Closed |
|
83
Barclays
London,
United Kingdom
| – | -$2K | -163 | Closed |
|
XENE Hedge Fund Activity: Q1 2020 in Review
70 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2020, worth a combined $314M — up 28% from $245M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new XENE positions and 13 closed out — a net gain of 5 holders — while 22 added to existing stakes and 18 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $28.2M. The largest seller was Acuta Capital Partners, cutting an estimated $4.12M.
- 70 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2020, up from 66 in Q4 2019.
- Funds reported $314M of Xenon Pharmaceuticals stock for Q1 2020, up 28% quarter-over-quarter.
- 18 funds opened new Xenon Pharmaceuticals positions in Q1 2020 and 13 closed out, a net change of +5 holders.
- The largest Xenon Pharmaceuticals buyer in Q1 2020 was Consonance Capital Management, an estimated $28.2M added.
- The largest Xenon Pharmaceuticals seller in Q1 2020 was Acuta Capital Partners, an estimated $4.12M sold.
Based on aggregated 13F filings for Q1 2020.